
MGTX Stock Forecast & Price Target
MGTX Analyst Ratings
Bulls say
MeiraGTx Holdings PLC is positioned favorably due to its advancements in applying genetic medicine to both rare and more prevalent diseases, thereby addressing significant unmet medical needs across multiple therapeutic areas. The company recently reported promising data from its first-in-human study of AAV-AIPL1, indicating a potential breakthrough in treating AIPL1-associated LCA4, which bodes well for investor sentiment and market potential. Additionally, a slight reduction in R&D expenses, down to $33.5 million from $34.9 million year-over-year, reflects efficient capital management amidst ongoing innovation efforts.
Bears say
MeiraGTx Holdings PLC faces significant risks in its pipeline development, particularly regarding regulatory approvals that are critical for product commercialization. Despite potential positive clinical results, any failure to secure regulatory approval would lead to downward revisions in projected financial outcomes. Additionally, if regulatory pathways become more complex or time-consuming than anticipated, this could further adversely affect the company's financial projections and overall market valuation.
This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.
MGTX Analyst Forecast & Price Prediction
Start investing in MGTX
Order type
Buy in
Order amount
Est. shares
0 shares